Variability in assessing treatment response: metastatic colorectal cancer as a paradigm. - Wikidata - wikimedia - TriplyDB

Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

http://www.wikidata.org/entity/Q35110520

about

Comparison of central and local serial CT assessments of metastatic renal cell carcinoma patients in a clinical phase IIB study.

P2860

Q38809318-6EC49E63-0635-4417-92DC-973D430AB593

P2860

Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

http://www.wikidata.org/entity/Q35110520

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

@ast

Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

@en

type

label

Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

@ast

Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

@en

prefLabel

Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

@ast

Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

@en

P1433

Q35110520-7A639FC0-4941-4345-9F60-F4941AB5E1CE

P1476

Q35110520-8F94F8D5-42CB-4E08-9FBA-69E29C4B2DC3

P2093

Q35110520-1AA684EA-A298-4D8E-A1EA-8A90BFE776EB

Q35110520-1CB82FF9-511F-4DB7-9CFF-8E1A358DB2A2

Q35110520-203983CF-DF7B-43E4-AB7C-B146883A62F5

Q35110520-3163E924-2F2F-4201-B01C-56C3B89C13B5

Q35110520-8CCACC20-DCD5-4B8D-B55F-B5E7315905E9

Q35110520-9736E2F5-728E-416D-80AC-C573CB020A5C

Q35110520-ABC6320C-25B0-4A8A-83BB-B102A214F223

Q35110520-C77F6442-A185-4494-9FCE-98447BE8DB52

P2860

Q35110520-01313C0C-8EED-4879-865B-BBDCF43A88F8

Q35110520-2051E9A5-5801-40C4-8E24-A647E635872A

Q35110520-3EB614B0-CC1C-49CB-A8FA-5015ECABCDAF

Q35110520-454565B9-CF8B-449C-BA4B-CB8911657F9D

Q35110520-459DED5B-67BC-4B37-89F0-5CC4D34F4C0F

Q35110520-4A14C9D3-D9E5-44AC-904D-AE4B0C8D1F12

Q35110520-64FDE63A-1646-4ED1-AEB6-A9F94BCB2A6E

Q35110520-66CA9C76-CA9C-4BA2-8BF3-D57B656F57F6

Q35110520-694A82FA-7317-4C49-8F2D-67B76E85BA96

Q35110520-82244563-8DBF-4BDA-87A1-81F23B961B76

P304

Q35110520-88D385C7-4FBA-48EE-A67E-280E65E00C5C

P31

Q35110520-EACD8A91-B026-4B40-A2DD-C7FCD5F24221

P356

Q35110520-90E6BCDF-CD51-4B69-A732-CCE5FD03FD94

P407

Q35110520-2A819DB7-B0AC-4D7D-A7C8-B4966538D59A

P433

Q35110520-0962327E-7644-4D82-B871-6ED7D127E8C0

P478

Q35110520-4D716F08-7446-41EA-B7FB-87DDB69F4FF4

P577

Q35110520-39E4AF81-F256-40C5-95B4-355C48D86688

P5875

Q35110520-6A268EA3-84E8-4D11-9C52-3C2E79FF686E

P698

Q35110520-B276141A-09E4-4838-84DF-F163E2EC23BE

P921

Q35110520-A96E430F-0F8F-4FB2-9608-63EE6FC19B2F

P932

Q35110520-D2D75E56-30BD-4C55-B190-B44083E9DA6A

P356

1078-0432.CCR-14-0245

P1433

Clinical Cancer Research

P1476

Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

@en

P2093

Binsheng Zhao

http://www.w3.org/2001/XMLSchema#string

David P Mozley

http://www.w3.org/2001/XMLSchema#string

Hyun-Ju Lee

http://www.w3.org/2001/XMLSchema#string

Jing Qi

http://www.w3.org/2001/XMLSchema#string

Lawrence H Schwartz

http://www.w3.org/2001/XMLSchema#string

Shing M Lee

http://www.w3.org/2001/XMLSchema#string

Thorsten Persigehl

http://www.w3.org/2001/XMLSchema#string

Yongqiang Tan

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Reporting results of cancer treatment

Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer.

Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities.

A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.

Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.

Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.

Assessing the effect of CT slice interval on unidimensional, bidimensional and volumetric measurements of solid tumours

P304

3560-3568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-0245

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262000546

http://www.w3.org/2001/XMLSchema#string

P698

24780294

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

4337392

http://www.w3.org/2001/XMLSchema#string